Anti-Inflammatory Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Anti-Inflammatory Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Anti-Inflammatory Drugs Market

The anti-Inflammatory drugs market size was valued at USD 93.88 billion in 2019, and the market is now projected to be USD 299.95 billion by 2032, exhibiting a CAGR of 9.4% during the forecast period of 2020-2032.

SARS-COV 2 has caused severe irritation to affect a patient which has encouraged drug production. The consequence of these problems led to increased R&D activities for the treatment. Various anti-incendiary medicines were used to manage fever, pain and irritation associated with the pandemic during the initial phase of the pandemic. On the other hand, concerns were raised regarding the potential unhelpful effects of antipyretic analgesics. This has raised concern for utilization of these medicines. These concerns stem from the fact that NSAIDs might potentially get worse the immune response and augment the threat of complications. Hence, the COVID-19 pandemic has created both opportunities and barriers for the anti-Inflammatory drugs market growth.

The anti-Inflammatory drugs market share globally has increased because of the growing probability of pipeline applicants. Increasing research expenditures for the improvement of biologics for the treatment of autoimmune inflammatory diseases has resulted in latent pipeline drugs. The companies are focusing on targeting broad provocative diseases with anti-tumor necrosis factor, interleukins, and others. The advantages of such drugs of monoclonal antibodies have changed the attention of pharmaceutical giants towards this area. In addition, the rising uptake of corticoid for the cure of asthma and chronic obstructive pulmonary disease (COPD) and the budding incidence of atopic dermatitis are predictable to put in force to the market growth.

The trend is growing focus on developing biosimilars with major pharmaceutical companies is fuelling the market growth. A lot of manufactures have shifted their attention to the development of biosimilars owing to the greater than ever demand and easy approval process when compared to a novel drug. Biosimilars of infliximab, adalimumab, and etanercept are endeavoring at attracting high revenue in the market with their reference biologics namely Humira, Ramicade, and Enbrel. This has become an important market drift.

Comprehensive Analysis of Anti-Inflammatory Drugs Market

The anti-Inflammatory drugs market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional evaluation considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically divided by drug class, application, route of administration, and distribution channel. The drug classes are NSAIDs, anti-inflammatory biologics, and corticosteroids. The applications comprise autoimmune-inflammatory diseases and respiratory. The route of administration involves oral, injection, inhalation, and topical; whereas the distribution channels include hospital pharmacy and retail pharmacy.

The North American region is conducive to the global anti-Inflammatory drugs market, leading to a recall of USD 41.39 billion owing to increasing demand for drugs, government-support, and significant research investments are propelling the market expansion.

The top players in the market play a vital role in the healthcare industry assuring industrial prospectus growth and setting market values. These players are Pfizer Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc., Eli Lilly and Company, Biogen, Amgen Inc., Novartis AG, and AbbVie Inc., these market players present a level-playing competitive landscape.

In December 2019, Union Chimique Belge did Phase 3 active-controlled BE SURE study in which they had declared positive results. It has compared the investigational IL-17A and IL-17F inhibitor bimekizumab to the TNF inhibitor adalimumab in the treatment of adults with moderate-to-severe plaque psoriasis.

Segmentation Table

Global Anti-Inflammatory Drugs Market Scope

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationBy Drug Class

Anti-inflammatory Biologics

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Corticosteroids

By Application

Autoimmune Inflammatory Diseases

Rheumatoid Arthritis

Psoriasis

Others

Respiratory Diseases

Others

By Route of Administration

Oral

Injection

Topical

Inhalation

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East& Africa (South Africa, GCC and the Rest of Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.